These mice express the tamoxifen-inducible Cre-ERT2 fusion protein (Cre-ERT2) under the control of the promoter/enhancer regions surrounding the site where the enhancer trap transgene randomly inserted. These mice may be useful for generating conditional mutations for studying gain or loss of function and/or fate mapping in brain tissues.
Ronald L Davis, The Scripps Research Institute Florida
Genetic Background | Generation |
---|---|
|
Allele Type |
---|
Transgenic (Recombinase-expressing, Inducible) |
Mice hemizygous for this enhancer trap transgene are viable and fertile, with expression of the Cre-ERT2 fusion gene under control of the promoter/enhancer regions surrounding the site where the enhancer trap transgene randomly inserted. Cre recombinase activity is observed in brain tissues following tamoxifen administration. The donating investigators may not have assessed expression in tissues other than brain. When these enhancer trap transgenic mice are bred with mice containing a loxP-flanked sequence of interest, tamoxifen-inducible, Cre-mediated recombination will result in deletion of the floxed sequence(s) in cre-expressing tissues in the offspring.
For characterization information, see images at the Allen Institute for Brain Science website (Et(cre/ERT2)4Rdav images).
The Cre-ERT2 fusion protein (Cre-ERT2) consists of Cre recombinase fused to a triple mutant form of the human estrogen receptor; which does not bind its natural ligand (17β-estradiol) at physiological concentrations but will bind the synthetic estrogen receptor ligands 4-hydroxytamoxifen (OHT or tamoxifen) and, with lesser sensitivity, ICI 182780. Restricted to the cytoplasm, Cre-ERT2 can only gain access to the nuclear compartment after exposure to tamoxifen. To counteract the mixed estrogen agonist effects of tamoxifen injections, which can result in late fetal abortions in pregnant mice, progesterone may be coadministered.
An enhancer trap transgenic approach was used to generate these mice. The TK-bgi-cre:ERT2-bGHpA transgene was designed with a thymidine kinase minimal promoter, a beta-globin intron, a CreERT2 fusion gene (Cre-ERT2; Cre recombinase fused to a G400V/M543A/L544A triple mutation of the human estrogen receptor ligand binding domain), and a bovine growth hormone polyA signal. This transgene was injected into C57BL/6J embryos. Founder mice (F0) from line 4 were bred to "C57 R26R" mutant mice from the Baylor College of Medicine (Gt(ROSA)26Sortm1Sor mice; similar to, but perhaps not as backcrossed as Stock No. 003474). The donating investigator reports that Cre-positive transgenic pups were bred to C57BL/6 mice or "C57 R26R" (see SNP note below) to maintain the colony. Upon arrival, transgenic mice were selectively bred to C57BL/6J inbred mice (Stock No. 000664) to remove the Gt(ROSA)26Sortm1Sor mutation.
A single nucleotide polymorphism (SNP) assay predicted these mice were 99% congenic onto the C57BL/6 genetic background (1 of 141 markers was not C57BL/6-allele type (on chromosomes 11). A 32 SNP panel analysis, with 27 markers covering all 19 chromosomes and the X chromosome, as well as 5 markers that distinguish between the C57BL/6J and C57BL/6N substrains, was performed on the rederived living colony at The Jackson Laboratory Repository. While the 27 markers throughout the genome suggested a C57BL/6 genetic background, at least 2 of 5 markers that determine C57BL/6J from C57BL/6N were found to be segregating. These data suggest the mice sent to The Jackson Laboratory Repository were on a mixed C57BL/6J ; C57BL/6N genetic background.
Expressed Gene | cre/ERT2, Cre recombinase and estrogen receptor 1 (human) fusion gene, |
---|---|
Site of Expression | Cre recombinase activity is observed in brain tissues following tamoxifen administration. |
Allele Name | enhancer trap 4, Ron Davis |
---|---|
Allele Type | Transgenic (Recombinase-expressing, Inducible) |
Allele Synonym(s) | |
Gene Symbol and Name | Et(cre/ERT2)4Rdav, enhancer trap 4, Ron Davis |
Gene Synonym(s) | |
Promoter | N/A, not available, |
Expressed Gene | cre/ERT2, Cre recombinase and estrogen receptor 1 (human) fusion gene, |
Site of Expression | Cre recombinase activity is observed in brain tissues following tamoxifen administration. |
Strain of Origin | C57BL/6J |
Chromosome | UN |
Molecular Note | An enhancer trap transgenic approach was used to generate these mice. The TK-bgi-cre:ERT2-bGHpA transgene was designed with the thymidine kinase (TK) minimal promoter driving a cre-ERT2 fusion gene (cre recombinase fused to a G400V/M543A/L544A triple mutation of the human estrogen receptor ligand binding domain). A beta globin intron separates the promoter from the cre gene and the bovine growth hormone polyadenylation signal follows the cre sequence. This transgene was injected into C57BL/6J embryos. Founder line 4 was established on a C57BL/6J genetic background. |
When maintaining a live colony, transgenic carrier mice may be bred together, to wildtype (noncarrier) siblings, or to C57BL/6J inbred mice (Stock No. 000664).
When using the B6(129S4)-Et(cre/ERT2)4Rdav/J mouse strain in a publication, please cite the originating article(s) and include JAX stock #009573 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Hemizygous or Non Carrier for Et(cre/ERT2)4Rdav |
Frozen Mouse Embryo | B6(129S4)-Et(cre/ERT2)4Rdav/J | $2595.00 |
Frozen Mouse Embryo | B6(129S4)-Et(cre/ERT2)4Rdav/J | $2595.00 |
Frozen Mouse Embryo | B6(129S4)-Et(cre/ERT2)4Rdav/J | $3373.50 |
Frozen Mouse Embryo | B6(129S4)-Et(cre/ERT2)4Rdav/J | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.